VALUATION HIGHLIGHTS

1. Neuroscience constitutes 41% of the Trefis price estimate for Medtronic's stock.
2. Medical Surgical constitutes 34% of the Trefis price estimate for Medtronic's stock.
3. Cardiac Rhythm Management constitutes 19% of the Trefis price estimate for Medtronic's stock.

WHAT HAS CHANGED?

Latest Earnings: Q3 Fiscal Year 2026

Medtronic reported Q3 FY2026 revenue of $9.02 billion, an 8.7% increase as reported and 6.0% on an organic basis, marking its highest enterprise revenue growth in ten quarters. Non-GAAP EPS reached $1.36, beating the guidance midpoint by three cents. Growth was primarily fueled by the Cardiovascular portfolio, which rose 13.8% (10.6% organic), led by an 80% surge in Cardiac Ablation Solutions following the rapid adoption of Pulsed Field Ablation (PFA) technologies. Despite the revenue beat, GAAP operating margins declined to 16.2% from 19.9% due to heavy R&D investment and potential tariff impacts, though non-GAAP margins remained resilient at 24.1%.

Note: Medtronic's FY'25 ended on April 25, 2025. Q3 FY'26 ended on January 23, 2026.

Commercial Launch of Hugo RAS System in the U.S.

In February 2026, Medtronic achieved a major strategic milestone with the first U.S. commercial surgical case of its Hugo robotic-assisted surgery (RAS) system at the Cleveland Clinic. Following FDA clearance for urologic procedures in late 2025, the Hugo system enters the lucrative U.S. market as a modular and mobile competitor to established platforms. Medtronic is now focused on expanding Hugo's indications into gynecology and general surgery. This launch, coupled with the pending IPO filing for its Diabetes business (MiniMed), signals a pivot toward high-growth technology segments and a more streamlined corporate structure focused on surgical innovation and cardiovascular leadership.

POTENTIAL UPSIDE & DOWNSIDE TO TREFIS PRICE

Below are key drivers of Medtronic's value that present opportunities for upside or downside to the current Trefis price estimate:

Cardiovascular Portfolio

• PFA Market Share Gains: Medtronic's Cardiac Ablation Solutions business grew 137% in the U.S. this quarter, driven by the PulseSelect and Affera PFA systems. As electrophysiologists shift away from traditional thermal ablation, Medtronic's "first-mover" advantage in PFA provides a significant tailwind. Upside potential exists if the Sphere-360 catheter, recently CE Marked in Europe, receives expedited U.S. approval, allowing Medtronic to capture a larger share of the $8 billion global ablation market.


• Renal Denervation Adoption: Following Medicare coverage for the Symplicity Spyral system, procedure volumes for uncontrolled hypertension are beginning to scale. If long-term clinical data continues to support sustained blood pressure reduction, this could transition from a niche therapy to a primary revenue driver for the Coronary & Peripheral Vascular segment, exceeding current conservative Trefis penetration estimates.

For additional details, select a division from the interactive Trefis split for Medtronic at the top of the page.

BUSINESS SUMMARY

Medtronic is the world's largest standalone medical technology company, operating across four primary portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its business model focuses on chronic disease management through "category leadership," where it aims to be #1 or #2 in every sub-segment it enters. The company is currently undergoing a multi-year transformation, divesting lower-growth businesses like Respiratory and Patient Monitoring (now Acute Care) and potentially spinning off its Diabetes segment to focus on high-margin, innovation-led areas such as robotic surgery and pulsed field ablation.

SOURCES OF VALUE

The Cardiovascular portfolio remains Medtronic's most valuable engine, consistently delivering double-digit organic growth and high-margin recurring revenue.

Cardiac Ablation and PFA Dominance

Medtronic has effectively redefined the electrophysiology landscape with its PFA portfolio. Unlike traditional methods that use heat or cold, PFA uses electrical fields to target heart tissue selectively. By securing early FDA clearances and building a robust clinical database (PULSED AF and SPHERE Per-AF), Medtronic has created high switching costs for hospitals that have integrated its specialized mapping and ablation workflows.

Cranial and Spinal Technology Integration

Medtronic's Neuroscience segment benefits from an "ecosystem moat" in the spine market. By integrating its Stealth AXiS navigation, O-arm imaging, and Mazor robotics, Medtronic offers a closed-loop surgical solution. This ecosystem ensures that hospital capital expenditures in Medtronic robotics lead to long-term recurring revenue from proprietary implants and disposables.

KEY TRENDS

Transition to Modular Surgical Robotics

The launch of the Hugo RAS system in the U.S. reflects a trend toward modularity in surgery. Unlike older, bulky systems, Hugo's modular arms and open console design allow hospitals to move the robot between different operating rooms, maximizing utilization and lowering the total cost of ownership—a critical factor for mid-sized hospitals facing capital budget constraints.

Separation of Slower-Growth Segments

Medtronic is actively pruning its portfolio to improve its overall growth profile. The IPO registration of the "MiniMed" Diabetes business follows earlier divestitures of the Dutch Obesity Clinic and the reorganization of the Patient Monitoring business. This strategy allows management to allocate capital more efficiently toward high-ROI R&D projects in the Cardiovascular and Surgical sectors.

Next-Generation Automated Insulin Delivery

In the Diabetes sector, the trend is toward "smart" multiple daily injection (MDI) systems. Medtronic's recent launch of the MiniMed Go system with the Simplera sensor integrates smart insulin pen data into a single app, targeting the large population of patients who do not yet use insulin pumps but require more advanced glucose management tools.